Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion (BRAVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01123564
Recruitment Status : Unknown
Verified May 2010 by University of Pecs.
Recruitment status was:  Recruiting
First Posted : May 14, 2010
Last Update Posted : May 14, 2010
University of Debrecen
Information provided by:
University of Pecs

Brief Summary:
This study aims to assess if Lucentis injection applied into the eye is superior to conventional treatment concerning the prevention of visual loss in patients having clinically significant macular edema secondary to retinal vein occlusion

Condition or disease Intervention/treatment Phase
Retinal Vein Occlusion Macular Edema Drug: ranibizumab Radiation: Argon laser treatment Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
Study Start Date : August 2009
Estimated Primary Completion Date : September 2011
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Lucentis (ranibizumab) Drug: ranibizumab
applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
Other Name: Lucentis intravitreal injection

Active Comparator: Laser Radiation: Argon laser treatment
Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
Other Name: Laser photocoagulation

Primary Outcome Measures :
  1. Efficacy compared to conventional treatment assessed by BCVA(best corrected visual acuity) [ Time Frame: 12 months ]
    To assess the superiority of intravitreal (IVT) ranibizumab to conventional treatment concerning prevention of visual loss or improvement of BCVA as determined by the mean change of BCVA tested by ETDRS chart compared to baseline in 12 months period, when intravitreal ranibizumab is applied monthly in the first 3 months period, and later when visual acuity (VA) decreases with more than 5 letters at any visit performed monthly.

Secondary Outcome Measures :
  1. Efficacy assessed by change in macular thickness [ Time Frame: 12 months with monthly assessment ]
    The efficacy of treatment concerning change of anatomical structure of macular region detected by Optical Coherence Tomography (OCT) - the mean change of macular thickness (micron) at each months of 1 year period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Macular edema persisting for more than 3 months period despite conventional medication.
  • Central retinal vein occlusion is confirmed by slit-lamp biomicroscopy and fluorescein angiography (FLAG).
  • Patients randomized into ranibizumab-treated group do not receive macular laser treatment.
  • Macular edema is defined by OCT: the thickness of central foveal area calculated by macular map analysis is above 280 μm and/or retinal thickness is above 330 μm at any region of the macula calculated by retinal thickness analysis.
  • Baseline visual acuity is less than 64 ETDRS letters (or 0.4 decimal equivalent).

Exclusion Criteria:

  • Diabetes mellitus
  • Additional vitreoretinal diseases
  • History of pars plana vitrectomy
  • Previous macular grid laser treatment
  • Intravitreal triamcinolone acetonid treatment
  • Complicated cataract surgery
  • Advanced glaucomatous damage of optic nerve head
  • Cataract (except mild, defined as grade 1 nuclear sclerosis and/or grade 1 posterior subcapsular cataract)
  • Age-related macular degeneration
  • Pregnancy and lactation
  • Women in childbearing potential who are not using double safe contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01123564

Contact: Zsolt Balla, MD +3672536141

Debrecen Medical and Health Science Center Dept of Ophthalmology Recruiting
Debrecen, Hungary, H-4012
Contact: Attila Vajas, MD   
Principal Investigator: Attila Vajas, MD         
University of Pecs, Medical School, Department of Ophthalmology Recruiting
Pecs, Hungary, H-7624
Contact: Zsolt Balla, MD    +3672536141   
Principal Investigator: Zsolt Balla, MD PhD         
Sponsors and Collaborators
University of Pecs
University of Debrecen
Principal Investigator: Zsolt Balla, MD PhD University of Pecs

Responsible Party: Zsolt Balla/assistant lecturer, University of Pecs, Medical Scool, Dept of Ophthalmology Identifier: NCT01123564     History of Changes
Other Study ID Numbers: CRFB002AHU02T
First Posted: May 14, 2010    Key Record Dates
Last Update Posted: May 14, 2010
Last Verified: May 2010

Keywords provided by University of Pecs:
macular edema secondary to retinal vein occlusion

Additional relevant MeSH terms:
Macular Edema
Retinal Vein Occlusion
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents